Linagliptin and newer DPP-4 inhibitors: Newer uses and newer indications

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 5, Issue 3, 2011, Pages 197-202

  Kalra, Sanjay ^a   Unnikrishnan, Ambika G ^b   Agrawal, Navneet ^c   Singh, Anupam K ^a  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^c DOTC   (India)

Author keywords

Diabetes; Dpp4 inhibitors; Hepatic safety; Incretins; Linagliptin; Oral hypoglycemics; Renal safety

Indexed keywords

ALOGLIPTIN; CHOLECYSTOKININ A RECEPTOR; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; GEMIGLIPTIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; KETOCONAZOLE; LINAGLIPTIN; MELOGLIPTIN; METFORMIN; MOXIFLOXACIN; OMEPRAZOLE; PIOGLITAZONE; RIFAMPICIN; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; VILDAGLIPTIN;

ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; HYPOGLYCEMIA; INFLAMMATION; MOLECULAR WEIGHT; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; WOUND HEALING;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; PATENTS AS TOPIC; PURINES; QUINAZOLINES;

EID: 80052856736     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221411797265926     Document Type: Review

References (47)

1. Yu DMT, Yao T-W, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010;277: 1126-1144.
2. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008; 13: 1634-1645.
3. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S. Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta 2005; 1751: 45-51.
4. Kirk JK, Oldham EC. Sitagliptin and vildagliptin: Efficacy of therapy in type 2 diabetes. Recent Pat Endocr Metab Immune Drug Discov 2008; 2(3): 162-171.
5. Suresh T, Saurabh A, Malla P, Haksar D, Raj BT, Kumar M. Saxagliptin; A new drug for the treatment of type 2 diabetes. Mini Rev Med Chem 2010; 10(8): 559-765.
6. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 2008; 13: 3648-3660.
7. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 Diabetes. Curr Opin Investing Drugs 2009; 10(10): 1091-1104.
8. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-2994.
9. Kushner P, Gorrell M. DPP-4 Inhibitors in Type 2 Diabetes: Importance of selective enzyme inhibition and implications for clinical use. J Fam Practice 2010; 59: 2.
10. Kirby MS, Yu DM, O'Connor SP, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010;118:31-41.
11. Heise T, Graefe-Modey EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, Pharmacodynemics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in made type2 diabetes patients. Diabetes Obes Metab 2009; 11: 786-789.
12. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3, 7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-563.
13. GraefeMody U, Huettner S, Stable H, Ring A, Dugi JA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010; 48 (6): 367-374.
14. Grafe-Mody EU, Jungik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between of the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Intl J Clin Pharmacol Ther 2010; 48 652-661.
15. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamics interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 2009; 25(8): 1963-1972.
16. Grafe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide in healthy subjects. Drug Metab Pharmacokinet 2011;26(2):123-129.
17. Sarashina A, Sesoko S, Nakashina M, Hayashi N, Taniguchi A, Horie Y, et al. Linagliptin, a dipeptidyle peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controolled trial of single and multiple escalatory doses in healthy adult male Japanese subjects. Clin Therapeutics 2010; 32(6): 1188-1204.
18. Freidrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle H-J. Evaluation of the pharmacokinetic interaction after multiple doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2011; 36(1): 17-24.
19. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody EU, Dugi KA. The novel, potent, and selective DPP-4 inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes (Abstr). Diabetes 2007; 56(Suppl 1): A157.
20. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle H-A, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of -cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2011; 13(3): 258-267.
21. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, doubleblind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
22. Gomis R, Esperado R-M, Jones R, Woerle H-J, Dugi K-A. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo controlled study. Diabetes Obes Metab 2011; 13(7):653-661.
23. Huttner S, GrafeMody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics and pharmacodynemics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase-4 in healthy male volunteers. J Clin Pharmacol 2008; 48: 1171-1178.
24. Ring A, Grafe-Mody U, Port A, Revollo I, Iovino M, Dugi KA. The DPP-4 inhibitor Linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br J Clin Pharmacol 2011; 72: 39-50.
25. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Goldstein BJ. Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-990.
26. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509.
27. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150-156.
28. Tradjenta™ (linagliptin) tablets. Highlights of prescribing information. Initial US Approval: (2011).
29. Grouzmann E, Livio F, Buclin T. Angiotensin converting enzyme and dipeptidyl peptidase IV inhibitors. An increased risk of angioedema. Hypertension 2009; 54: 468.
30. Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008; 10(11):1057-1061.
31. Andukuri R, Drincic A, Rendell M. Alogliptin: A new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obesity 2009; 2: 117-126.
32. Alogliptin delayed at least two years. Available at: www.theheart.org/article/983133.do#bib_1. [Accessed on January 17, 2011].
33. Cardiovascular outcomes study of alogliptin in subjects with type 2 diabetes and acute coronary syndrome (EXAMINE). Available at http://clinicaltrials.gov.ct2/show/NCT00968708. [Accessed on January 17, 2011].
34. th World Diabetes Congress Book 2009; 454.
35. Frederich, R., Edelberg, J., Fiedorek, F.T. Methods for preventing or reducing risk of mortality. US20100256153 (2010).
36. Berger, R., Edmondson, S., Hansen, S., Zhu, C. Substituted inidazole-4 carboxamides as cholecystokinin-1 receptor modulators. US20100311649 (2010).
37. Cruz, A. Combined use of DPP-4 inhibitors and gastrin compounds. US20100144613 (2010).
38. Biftu, T., Chen, P., Feng, D., Weber, A.E. Substituted [1,2,4] triazolo [1,5-a] pyrazines as dipeptidyl peptidase -IV inhibitors. US7812027 (2010).
39. Biftu, T., Cox, J., Feng, D., Mastracchio, A., Qion, X., Weber, A.E. Aminocyclohexanes as dipeptidyl peptidase IV inhibitors for the treatment or prevention. US7750034 (2010).
40. Cohen, F., Fairbrother, W.J., Qvan, C., Sutherlen, D.P., Wolf, B.B. Fibroblast activation protein inhibitor compounds and methods. US20060276435 (2006).
41. Hausenloy DJ, Wynne AM, Theodorou L, Mocanu MM, Yellon DM. Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose sensitive manner. Heart 2010; 96: e11 doi: 10.1136/hrt.2010.205781.7.
42. Yanai H, Masui Y, Yoshikawa R, Kunimatsu J, Kaneko H. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diabetes 2010; 1(3): 99-100.
43. Hughes, T.E. Vildagliptin for treating general peripheral neuropathies. US20100160408 (2010).
44. Hughes, T.E. DPP-IV inhibitors for treating neurodegeneration and cognitive disorders. US20090017015 (2009).
45. Linke A, Frank S, Mark M, Klein T. The DPP-4 inhibitor linagliptin (BI 1356) improves wound healing in ob/ob mice. Diabetes 2009;58(Suppl.1):A161.
46. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging class for inflammatory disease? Trends Pharmacol Sci 2009; 30:600-607.
47. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999; 85 (1): 9-24.